Q32 Bio
PublicQ32 Bio is now publicly traded
The data on this page reflects Q32 Bio's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Placement
Mar 25, 2024
Total Funding Raised
$148M
Company Overview
Q32 Bio operates in Healthcare and is based in Waltham, Massachusetts. It has raised $148M.
Q32 Bio (NAS: QTTB) is a biotechnology company focused on developing innovative biologics to restore immune balance in patients with autoimmune and inflammatory diseases through antibody-based therapeutics.
Sector
Healthcare
AI Layer
Non-AI
Q32 Bio Comparables
Compare Q32 Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Attovia Therapeutics | 61% | |
| Linno Pharmaceuticals Inc. | 60% | |
| Cerium Pharmaceuticals, Inc. | 54% |
For institutional investors. Book with your work email.
Q32 Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Mar 25, 2024 | ||||
| Series B | Oct 29, 2020 | ||||
| Series A | May 27, 2020 |
For institutional investors. Book with your work email.
Q32 Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Private Placement |
| Osage University Partners | Series B, Private Placement |
| OrbiMed | Series A, Private Placement, Series B |
| Accomplice | Series B, Private Placement, Series A |
| Acorn Bioventures | Private Placement, Series B |
| Abingworth | Series A, Series B, Private Placement |
| Sanofi Ventures | Series A, Series B, Private Placement |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 21, 2026
Q32 Bio Inc. announces late-breaking oral and poster presentations of additional 36-week and initial 16-week off-drug-period results from Part B of the SIGNAL-AA clinical trial at the European Academy of Dermatology and Venereology Congress 2026 in Austria in Fall '26.
- hiresSep 14, 2026
Q32 Bio Inc. announces the appointment of Ellie Hershberger, PharmD, as chief development officer on Sep 14th '26 as it transitions into a late clinical-stage company and prepares to advance bempikibart.
- hiresSep 14, 2026
Q32 Bio Inc. appoints José Trevejo as chief medical officer as it prepares to advance its lead alopecia areata drug candidate into a registration-directed program in Massachusetts on Sep 14th '26.
- hiresSep 14, 2026
On Sep 14th '26, Q32 Bio Inc. appoints José Trevejo, MD, PhD, as chief medical officer as it transitions into a late clinical-stage company.
- hiresSep 14, 2026
Q32 Bio Inc. appoints Ellie Hershberger as chief development officer as it prepares bempikibart for a registration-directed program in severe or very severe alopecia areata in H1 '27.
For institutional investors. Book with your work email.
Q32 Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.